Sanofi, Korean biotech Lemonex ink material transfer agreement
South Korean biotech Lemonex Inc. has signed a material transfer agreement (MTA) with global pharmaceutical giant Sanofi S.A. to use the Korean bi...
Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum
South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has ob...
Korean bio firms look to pills, patches for people who fear needles
Getting shots of a drug or vaccine over a long period is not easy for many people.That's probably why global biopharmaceutical companies and biotech...
Celltrion Healthcare logs record-high Q2 revenue on back of Remsima
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quar...
TiumBio inks licensing deal with China's Hansoh for endometriosis drug
South Korean biotech TiumBio Co. has signed a technology transfer agreement of its endometriosis and uterine myoma treatment candidate with China&rs...
Korean snack shares surge, Beijing halts baked goods imports from Taiwan
Shares of South Korean confectionery and packaged snack makers skyrocketed after the Chinese government announced its decision to temporarily halt t...
SK Biopharmaceuticals signs epilepsy drug deal with Brazil’s Eurofarma
South Korea’s SK Biopharmaceuticals Co. has signed a deal to license out its technology for Cenobamate, an antiepileptic drug, to Brazil&rsquo...
Korean biotech firms fold COVID-19 therapeutics development businesses
A string of South Korean pharmaceutical and biotech companies are waving the white flag when it comes to developing COVID-19 treatments. As the...
1 in 4 biotech firms struggles with decreasing cash reserves
South Korea’s biotechnology firms – public and private alike – are facing increasingly negative financial conditions. T...
Pharma companies jump into $3 bn pet care market
South Korean pharmaceutical companies are jumping into the animal medicine and diagnostics market to target the rapidly growing pet care market, whi...
KT, Hanmi-invested therapeutics maker Digital Pharm launched
Digital Pharm, jointly invested in by KT Corp. and Hanmi Pharmaceutical Co., held an official inauguration ceremony last week, the company announced...
LG Chem receives FDA nod for CUE-102 cancer treatment phase 1 trials
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., has received the US Food and Drug Administration’s approval for phase 1 cli...
Shinsegae to resume soju business targeting Southeast Asia
South Korea’s Shinsegae L&B Co. is set to resume its distilled spirit soju business as early as the end of May, aiming for exports to some...
HK inno.N receives sales permit for ulcer treatment in China
HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...
Hanmi stands out with own drugs as Korean rivals sell imports
South Korea’s Hanmi Pharmaceutical Co. generated sales of more than 1 trillion won ($812.3 million) from its own medicines last year on strong...
SK Chemicals to invest $1.6 bn in green, biopharmaceutical sectors
South Korea’s SK Chemicals plans to invest more than 2 trillion won ($1.6 billion) in eco-friendly material and biopharmaceutical businesses.T...
Korea Hanmi to launch blockbuster hypertension drug in China
South Korea’s Hanmi Pharmaceutical Co. is set to launch its blockbuster high blood pressure drug Amosartan in China, the world’s largest...
Korea’s Voronoi in talks with global firms on drug designs
South Korea’s biotechnology startup Voronoi Inc. is in talks with global biomedical companies on drug designs as it aims to expand the busines...
Kolon resumes Invossa phase 3 clinical trials in US
Kolon TissueGene Inc., the cell therapies unit of South Korean pharmaceutical company Kolon Life Science Inc., said on Dec. 28 it has resumed admi...
HK inno.N’s K-CAB a blockbuster drug with $843 million exports
South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal...
Korea’s MedPacto, Merck plan phase 3 trials of colorectal cancer drug
MedPacto Inc., a South Korean biotechnology company that develops therapeutics for cancer and autoimmune diseases, has agreed with global drugmaker ...
Celltrion looks beyond biosimilars to develop its own mRNA drugs
South Korea’s Celltrion Inc. has long been a biosimilar player, producing replicas of original drugs, a growing market in the pandemic era.Ear...
Samsung Bioepis gets FDA approval for Lucentis biosimilar Byooviz
Samsung Bioepis Co., a leading South Korean biopharmaceutical company, has received approval from the US Food and Drug Administration for its Byoovi...
High-priced drugs add to pressure for Korea's healthcare reform
A number of new rare disease treatments, approved in South Korea over the past year, are still unaffordable for the public because of their price ta...
Samsung Biologics gears up to produce mRNA drug substance
South Korea’s Samsung Biologics Co. is gearing up for the drug substance (DS) sector of the messenger ribonucleic acid (mRNA)-based COVID-19 v...
Daewoong Pharmaceutical aims to top $4 bn in sales by 2027
South Korea-based Daewoong Pharmaceutical Co. is hoping to achieve 5 trillion won ($4.4 billion) in sales by 2027, meaning that the company aims to ...
LegoChem’s biotech platform drives 28% share price spike over last month
The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...
SK Biopharm aims to make it to global top 10 healthcare firms by 2030
South Korea’s SK Biopharmaceuticals Co. said on Friday it aspires to become one of the world’s top 10 healthcare companies by 2030 with ...
Eyegene to kick off Korea’s first mRNA clinical trial
Eyegene Inc. will be South Korea’s first vaccine maker to conduct clinical tests of messenger ribonucleic acid (mRNA) COVID-19 vaccines. Ealie...
Celltrion, Mirae to take largest stake in UK biotech firm
South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...
